The Journal of Infectious Diseases最新文献_第10页

What is the economic benefit of annual COVID-19 vaccination from the adult individual perspective? 从成人个人角度来看，每年接种 COVID-19 疫苗的经济效益如何？

The Journal of Infectious Diseases Pub Date : 2024-04-06 DOI: 10.1093/infdis/jiae179

Sarah M Bartsch, Kelly J O’Shea, Colleen Weatherwax, Ulrich Strych, Kavya Velmurugan, Danielle C John, Maria Elena Bottazzi, Mustafa Hussein, Marie F Martinez, Kevin L Chin, Allan Ciciriello, Jessie Heneghan, Alexis Dibbs, Sheryl A Scannell, Peter J Hotez, Bruce Y Lee

{"title":"What is the economic benefit of annual COVID-19 vaccination from the adult individual perspective?","authors":"Sarah M Bartsch, Kelly J O’Shea, Colleen Weatherwax, Ulrich Strych, Kavya Velmurugan, Danielle C John, Maria Elena Bottazzi, Mustafa Hussein, Marie F Martinez, Kevin L Chin, Allan Ciciriello, Jessie Heneghan, Alexis Dibbs, Sheryl A Scannell, Peter J Hotez, Bruce Y Lee","doi":"10.1093/infdis/jiae179","DOIUrl":"https://doi.org/10.1093/infdis/jiae179","url":null,"abstract":"Background With COVID-19 vaccination no longer mandated by many businesses/organizations, it is now up to individuals to decide whether to get any new boosters/updated vaccines going forward. Methods We developed a Markov model representing the potential clinical/economic outcomes from an individual perspective in the United States of getting versus not getting an annual COVID-19 vaccine. Results For an 18-49-year-old, getting vaccinated at its current price ($60) can save the individual on average $30-$603 if the individual is uninsured and $4-$437 if the individual has private insurance, as long as the starting vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ≥50% and the weekly risk of getting infected is ≥0.2%, corresponding to an individual interacting with 9 other people in a day under Winter 2023-2024 Omicron SARS-CoV-2 variant conditions with an average infection prevalence of 10%. For a 50-64-year-old, these cost-savings increase to $111-$1,278 and $119-$1,706, for someone without and with insurance, respectively. The risk threshold increases to ≥0.4% (interacting with 19 people/day), when the individual has 13.4% pre-existing protection against infection (e.g., vaccinated 9 months earlier). Conclusion There is both clinical and economic incentive for the individual to continue to get vaccinated against COVID-19 each year.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140533922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Membrane Lipids Augment Cell Envelope Stress Signaling via the MadRS System to Defend Against Antimicrobial Peptides and Antibiotics in Enterococcus faecalis 膜脂通过 MadRS 系统增强细胞包膜压力信号，以抵御粪肠球菌中的抗菌肽和抗生素

The Journal of Infectious Diseases Pub Date : 2024-04-05 DOI: 10.1093/infdis/jiae173

William R Miller, April Nguyen, Kavindra V Singh, Samie Rizvi, Ayesha Khan, Sam G Erickson, Stephanie L Egge, Melissa Cruz, An Q Dinh, Lorena Diaz, Philip C Thornton, Rutan Zhang, Libin Xu, Danielle A Garsin, Yousif Shamoo, Cesar A Arias

{"title":"Membrane Lipids Augment Cell Envelope Stress Signaling via the MadRS System to Defend Against Antimicrobial Peptides and Antibiotics in Enterococcus faecalis","authors":"William R Miller, April Nguyen, Kavindra V Singh, Samie Rizvi, Ayesha Khan, Sam G Erickson, Stephanie L Egge, Melissa Cruz, An Q Dinh, Lorena Diaz, Philip C Thornton, Rutan Zhang, Libin Xu, Danielle A Garsin, Yousif Shamoo, Cesar A Arias","doi":"10.1093/infdis/jiae173","DOIUrl":"https://doi.org/10.1093/infdis/jiae173","url":null,"abstract":"Enterococci have evolved resistance mechanisms to protect their cell envelopes against bacteriocins and host cationic antimicrobial peptides (CAMPs) produced in the gastrointestinal environment. Activation of the membrane stress response has also been tied to resistance to the lipopeptide antibiotic daptomycin. However, the actual effectors mediating resistance have not been elucidated. Here, we show that the MadRS (formerly YxdJK) membrane antimicrobial peptide defense system controls a network of genes, including a previously uncharacterized three gene operon (madEFG) that protects the E. faecalis cell envelope from antimicrobial peptides. Constitutive activation of the system confers protection against CAMPs and daptomycin in the absence of a functional LiaFSR system and leads to persistence of cardiac microlesions in vivo. Moreover, changes in the lipid cell membrane environment alter CAMP susceptibility and expression of the MadRS system. Thus, we provide a framework supporting a multilayered envelope defense mechanism for resistance and survival coupled to virulence.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140352112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AMPing up the Pressure: Cell envelope signaling protects Enterococcus faecalis from antimicrobial peptides. AMPing up the Pressure：细胞包膜信号保护粪肠球菌免受抗菌肽的侵害。

The Journal of Infectious Diseases Pub Date : 2024-04-05 DOI: 10.1093/infdis/jiae175

Adeline Supandy, D. Van Tyne

引用次数: 0

Prevotella timonensis bacteria associated with vaginal dysbiosis enhance HIV-1 susceptibility of vaginal CD4+ T cells 与阴道菌群失调有关的蒂莫纳氏前驱菌提高了阴道 CD4+ T 细胞对 HIV-1 的易感性

The Journal of Infectious Diseases Pub Date : 2024-04-04 DOI: 10.1093/infdis/jiae166

Nienke H van Teijlingen, Marleen Y van Smoorenburg, Ramin Sarrami-Forooshani, Esther M Zijlstra-Willems, John L van Hamme, Hanneke Borgdorff, Janneke HHM van de Wijgert, Elisabeth van Leeuwen, Joris A M van der Post, Karin Strijbis, Carla M S Ribeiro, Teunis B H Geijtenbeek

引用次数: 0

Analysis of a large SARS-CoV-2 (Alpha) outbreak in a Catalan prison using conventional and genomic epidemiology. 利用传统流行病学和基因组流行病学分析加泰罗尼亚一所监狱爆发的大规模 SARS-CoV-2 (阿尔法)疫情。

The Journal of Infectious Diseases Pub Date : 2024-04-04 DOI: 10.1093/infdis/jiae161

A. Bordoy, Xavier Vallès, J. Fernández-Náger, Montserrat Sánchez-Roig, Juan Fernandez-Recio, V. Saludes, M. Noguera-Julián, Ignacio Blanco, E. Martró

引用次数: 0

Respiratory syncytial virus vs. Influenza virus infection: mortality and morbidity comparison over 7 epidemic seasons in an elderly population 呼吸道合胞病毒感染与流感病毒感染：老年人群 7 个流行季节的死亡率和发病率比较

The Journal of Infectious Diseases Pub Date : 2024-04-04 DOI: 10.1093/infdis/jiae171

C Recto, S Fourati, M Khellaf, J-M Pawlotsky, N De Prost, H Diakonoff, C Donadio, L Pouga, C de Tymowski, C Kassasseya

{"title":"Respiratory syncytial virus vs. Influenza virus infection: mortality and morbidity comparison over 7 epidemic seasons in an elderly population","authors":"C Recto, S Fourati, M Khellaf, J-M Pawlotsky, N De Prost, H Diakonoff, C Donadio, L Pouga, C de Tymowski, C Kassasseya","doi":"10.1093/infdis/jiae171","DOIUrl":"https://doi.org/10.1093/infdis/jiae171","url":null,"abstract":"Background Respiratory syncytial virus (RSV) infection is gaining interest due to the recent development of vaccines, but it is still misdiagnosed in the elderly. The primary objective was to compare all-cause mortality at day 30. Secondary objectives were to compare clinical presentation, and rates of consolidative pneumonia, hospitalization, and intensive care unit (ICU) admission. Methods Single-centre retrospective study conducted in a French university hospital during 7 epidemic seasons. All patients aged ≥75 years were included. Results 558 patients were included: 125 with RSV and 433 with Influenza. Median age was 84.8 years. RSV patients had more respiratory symptoms (wheezing, dyspnea), whereas Influenza patients had more general symptoms (fever, asthenia, myalgia). Consolidative pneumonia (28.8% vs. 17.2%; p = 0.004), hospitalization rates (83.2% vs. 70%; p = 0.003), ICU admissions (7.2% vs. 3.0%; p = 0.034) and length of stay (9 days [2-16] vs. 5 days [0-12]; p = 0.002), were higher in the RSV group. Mortality rates at day 30 were comparable (RSV 9.6%, Influenza 9.7%; p = 0.973). Conclusions This study included the largest cohort of RSV-infected patients aged over 75, documented in-depth thus far. RSV shares a comparable mortality rate with Influenza but is associated with higher rates of consolidative pneumonia, hospitalization, ICU admissions, and extended hospital stays.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140349048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimating the Potential Public Health Value of BCG Revaccination 估算卡介苗再接种的潜在公共卫生价值

The Journal of Infectious Diseases Pub Date : 2024-04-03 DOI: 10.1093/infdis/jiae089

Rebecca A Clark, Tom Sumner, Chathika K Weerasuriya, Roel Bakker, Thomas J Scriba, Richard G White

引用次数: 0

High Frequency of Prior SARS-CoV-2 Infection by Sensitive Nucleocapsid Assays 通过灵敏的核头壳检测发现 SARS-CoV-2 之前的高感染率

The Journal of Infectious Diseases Pub Date : 2024-04-03 DOI: 10.1093/infdis/jiae174

Joseph P Nkolola, Jinyan Liu, Ai-ris Y Collier, Catherine Jacob-Dolan, Yasmeen Senussi, Ella Borberg, Zoe Swank, David R Walt, Dan H Barouch

引用次数: 0

Cytotoxic lymphocyte-monocyte complex reflects the dynamics of COVID-19 systemic immune response 细胞毒性淋巴细胞-单核细胞复合体反映了 COVID-19 全身免疫反应的动态变化

The Journal of Infectious Diseases Pub Date : 2024-02-01 DOI: 10.1093/infdis/jiae048

Jiajia Lin, Shiyu Bai, Liheng He, Ye Yang, Xiyue Li, Liulin Luo, Ying Wang, Ying-ying Chen, Jinhong Qin, Yi Zhong

{"title":"Cytotoxic lymphocyte-monocyte complex reflects the dynamics of COVID-19 systemic immune response","authors":"Jiajia Lin, Shiyu Bai, Liheng He, Ye Yang, Xiyue Li, Liulin Luo, Ying Wang, Ying-ying Chen, Jinhong Qin, Yi Zhong","doi":"10.1093/infdis/jiae048","DOIUrl":"https://doi.org/10.1093/infdis/jiae048","url":null,"abstract":"SARS-CoV-2 infection causes a variety of clinical manifestations, many of which originate from altered immune responses, either locally or systemically. Immune cell crosstalk occurs mainly in lymphoid organs. However, systemic cell interaction specific to COVID-19 has not been well characterized. Here, by employing single cell RNA sequencing and imaging flow cytometry analysis, we unraveled, in peripheral blood, a heterogeneous group of cell complexes formed by the adherence of CD14+ monocytes to different cytotoxic lymphocytes, including SARS-CoV-2-specific CD8+ T cells, γδT and NKT cells. These lymphocytes attached to CD14+ monocytes that showing enhanced inflammasome activation and pyroptosis-induced cell death in progression stage, whereas in convalescent phase, CD14+ monocytes with elevated antigen presentation potential were targeted by cytotoxic lymphocytes, thereby restricting the excessive immune activation. Collectively, our study reports previously unrecognized cell-cell interplay in SARS-CoV-2 specific immune response, providing new insight into the intricacy of dynamic immune cell interaction representing anti-viral defense.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139660234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How Global Collaboration Can Improve the Medical Countermeasure Life Cycle for Infectious Disease Outbreaks: A BARDA Perspective 全球合作如何改善传染病爆发的医疗对策生命周期：BARDA 的视角

The Journal of Infectious Diseases Pub Date : 2024-01-20 DOI: 10.1093/infdis/jiae017

Jessica Swenson, Gary Disbrow, Robert A Johnson

{"title":"How Global Collaboration Can Improve the Medical Countermeasure Life Cycle for Infectious Disease Outbreaks: A BARDA Perspective","authors":"Jessica Swenson, Gary Disbrow, Robert A Johnson","doi":"10.1093/infdis/jiae017","DOIUrl":"https://doi.org/10.1093/infdis/jiae017","url":null,"abstract":"Infectious disease outbreaks have become increasingly common and require global partnership for adequate preparedness and response. During outbreaks, medical countermeasures (MCMs)—vaccines, therapeutics, and diagnostics—need to reach patients quickly. BARDA utilizes public-private partnerships to support advanced development of MCMs through U.S. FDA approval against a variety of threats within its mission space. MCM preparedness and response must be approached as an integrated life cycle, not as independent steps. Recent filovirus outbreaks in Africa exemplify that collaborative relationships are critical for emergency response, and products with regulatory approval can expand access and reach patients quicker than investigational products. Unfortunately, insufficient funding globally and differences in funders’ prioritization puts gains and future efforts at risk. Of primary concern is a) lack of a feasible regulatory path and clinical capability to achieve regulatory approval for new MCMs for many diseases; and b) the need for partners with the mandate, funding, and capabilities to support the life cycle activities following development—long-term sustainment of manufacturing capability and stockpiling of licensed products to support international outbreaks. Finding partners that complement BARDA’s mission and support the MCM life cycle will be a key component in deciding which MCM development efforts can be supported. Without collaboration, the global community runs the risk of losing the capabilities built through years of investment and being underprepared to combat future threats. Synergies between funders that have different roles and responsibilities within the MCM life cycle are critical to MCM availability and create long-term sustainment of products to ensure access.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139506063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0